ENTA

ENTA

USD

Enanta Pharmaceuticals Inc. Common Stock

$7.950+0.385 (5.089%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$7.565

最高价

$8.470

最低价

$7.475

成交量

0.24M

公司基本面

市值

169.9M

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

0.20M

交易所

NMS

货币

USD

52周价格范围

最低价 $4.09当前价 $7.950最高价 $17.235

相关新闻

BusinessWire

Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus

MAVYRET® (glecaprevir/pibrentasvir) is Now the Only Direct Acting Antiviral Therapy Approved to Treat Patients with Acute Hepatitis C Virus (HCV) in Eight Weeks with a 96% Cure Rate1*† FDA Approval Now

查看更多
Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus
Analyst Upgrades

JMP Securities Maintains Market Outperform on Enanta Pharma, Raises Price Target to $24

JMP Securities analyst Roy Buchanan maintains Enanta Pharma with a Market Outperform and raises the price target from $23 to $24.

查看更多
JMP Securities Maintains Market Outperform on Enanta Pharma, Raises Price Target to $24
BusinessWire

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D.,

查看更多
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
BusinessWire

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company's

查看更多
Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting